Published in Ann Surg Oncol on July 23, 2015
Identification and management of women with a family history of breast cancer: Practical guide for clinicians. Can Fam Physician (2016) 0.75
Breast Cancer Profile among Patients with a History of Chemoprevention. Int J Breast Cancer (2016) 0.75
Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. Oncologist (2017) 0.75
Physician and Patient Barriers to Breast Cancer Preventive Therapy. Curr Breast Cancer Rep (2016) 0.75
Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res (2017) 0.75
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst (2001) 5.97
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
A breast cancer prediction model incorporating familial and personal risk factors. Stat Med (2004) 5.30
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2013) 4.20
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2014) 4.11
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst (2004) 3.28
Adult weight change and risk of postmenopausal breast cancer. JAMA (2006) 3.11
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. Cancer Causes Control (2006) 2.17
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol (2001) 1.94
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat (2012) 1.66
Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol (1991) 1.65
Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point. Cancer Epidemiol Biomarkers Prev (2007) 1.57
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst (2011) 1.51
Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol (2004) 1.46
Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol (2010) 1.45
Physical activity and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev (2006) 1.38
Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res (2012) 1.24
Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2013) 1.21
Factors affecting breast cancer risk reduction practices among California physicians. Prev Med (2004) 1.14
Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev (2000) 1.09
Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer (2014) 1.01
Breast cancer prevention: patient decision making and risk communication in the high risk setting. Breast J (2009) 0.93
Mammographic breast density: impact on breast cancer risk and implications for screening. Radiographics (2015) 0.86
Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model. Carcinogenesis (2005) 0.83
Personalized assessment and management of women at risk for breast cancer in North America. Womens Health (Lond Engl) (2015) 0.78
Prophylactic mastectomy: a treatment alternative for Hodgkin survivors? Clin Breast Cancer (2013) 0.77
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol (2009) 1.54
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Breast Cancer Risk Reduction, Version 2.2015. J Natl Compr Canc Netw (2015) 1.12
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) (2012) 1.01
Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat (2006) 0.98
Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res (2002) 0.89
Breast cancer risk reduction. J Natl Compr Canc Netw (2010) 0.88
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt) (2010) 0.88
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged <or=55 years. Breast Cancer Res Treat (2007) 0.83
Exemestane in the prevention setting. Ther Adv Med Oncol (2012) 0.79
Educating women about breast cancer. An intervention for women with a family history of breast cancer. Can Fam Physician (2003) 0.79
Ultrasound for the screening of breast cancer. Curr Oncol Rep (2008) 0.78
A human papillomavirus testing system in women with abnormal Pap results: a comparison study with follow-up biopsies. Acta Cytol (2007) 0.78
Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer (2013) 0.78
An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis. Biomark Cancer (2013) 0.76
Most lobular carcinoma in situ and atypical lobular hyperplasia diagnosed on core needle biopsy can be managed clinically with radiologic follow-up in a multidisciplinary setting. Cancer Med (2014) 0.76
Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study. Brain Imaging Behav (2013) 0.76
CT screening for lung cancer. Curr Oncol Rep (2007) 0.75
The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results. Cancer Cytopathol (2012) 0.75
Physical Activity Algorithm In A Comprehensive Cancer Center.: 1879 Board #31 June 2, 3: 30 PM - 5: 00 PM. Med Sci Sports Exerc (2016) 0.75
Breast cancer risk reduction therapy: the low-hanging fruit. J Natl Compr Canc Netw (2015) 0.75